Renaissance Technologies
ATNM icon

Renaissance Technologies’s Actinium Pharmaceuticals ATNM Stock Holding History

Renaissance Technologies’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$469K Buy
471,600
+80,816
+21% +$96.1K ﹤0.01% 2631
2025
Q4 		$531K Buy
390,784
+102,154
+35% +$149K ﹤0.01% 2551
2025
Q3 		$462K Buy
288,630
+79,129
+38% +$129K ﹤0.01% 2834
2025
Q2 		$293K Buy
209,501
+151,901
+264% +$227K ﹤0.01% 3047
2025
Q1 		$92.7K Sell
57,600
-132,800
-70% -$169K ﹤0.01% 3209
2024
Q4 		$240K Buy
190,400
+63,400
+50% +$98.4K ﹤0.01% 3114
2024
Q3 		$239K Buy
127,000
+107,800
+561% +$426K ﹤0.01% 3065
2024
Q2 		$142K Buy
+19,200
New +$158K ﹤0.01% 3115
2023
Q3 		– Sell
-48,302
Closed -$358K – 3645
2023
Q2 		$358K Sell
48,302
-53,898
-53% -$459K ﹤0.01% 3048
2023
Q1 		$966K Sell
102,200
-57,400
-36% -$606K ﹤0.01% 2500
2022
Q4 		$1.7M Buy
159,600
+81,300
+104% +$825K ﹤0.01% 2179
2022
Q3 		$578K Buy
78,300
+20,600
+36% +$128K ﹤0.01% 2845
2022
Q2 		$278K Buy
+57,700
New +$328K ﹤0.01% 3500
2020
Q3 		– Sell
-120,212
Closed -$1.27M – 3363
2020
Q2 		$1.27M Buy
120,212
+80,664
+204% +$611K ﹤0.01% 2429
2020
Q1 		$230K Buy
39,548
+6,537
+20% +$46.4K ﹤0.01% 3066
2019
Q4 		$216K Buy
33,011
+16,325
+98% +$113K ﹤0.01% 3175
2019
Q3 		$115K Buy
16,686
+9,632
+137% +$67K ﹤0.01% 3249
2019
Q2 		$52K Buy
7,054
+2,409
+52% +$24.2K ﹤0.01% 3450
2019
Q1 		$67K Buy
4,645
+1,911
+70% +$30.5K ﹤0.01% 3342
2018
Q4 		$32K Sell
2,734
-11,385
-81% -$194K ﹤0.01% 3307
2018
Q3 		$314K Buy
14,119
+1,202
+9% +$24.5K ﹤0.01% 3003
2018
Q2 		$248K Buy
12,917
+11,974
+1,270% +$152K ﹤0.01% 3022
2018
Q1 		$10K Buy
+943
New +$16K ﹤0.01% 3336
2017
Q3 		– Sell
-382
Closed -$14K – 3195
2017
Q2 		$14K Sell
382
-2,729
-88% -$114K ﹤0.01% 3162
2017
Q1 		$141K Sell
3,111
-707
-19% -$27.1K ﹤0.01% 3040
2016
Q4 		$100K Buy
+3,818
New +$119K ﹤0.01% 3102
2015
Q2 		– Sell
-3,160
Closed -$234K – 3214
2015
Q1 		$234K Buy
+3,160
New +$376K ﹤0.01% 2833

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies's ATNM Position: Q1 2026 in Review

Renaissance Technologies increased its Actinium Pharmaceuticals (ATNM) stake by 21% in Q1 2026, buying an estimated $96.1K and bringing the position to 471,600 shares worth $469K. The position accounts for ﹤0.01% of the portfolio, ranked #2631.

Renaissance Technologies first reported a position in ATNM in Q1 2015 and has held it in 27 quarters since. The position peaked at $1.7M in Q4 2022. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Renaissance Technologies held 471,600 shares of Actinium Pharmaceuticals worth $469K as of Q1 2026.
  • Renaissance Technologies bought 80,816 Actinium Pharmaceuticals shares in Q1 2026, an estimated $96.1K.
  • Actinium Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2631 holding.
  • Renaissance Technologies first reported a position in Actinium Pharmaceuticals in Q1 2015 and has held it in 27 quarters since.
  • Renaissance Technologies's Actinium Pharmaceuticals position peaked at $1.7M in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.